EXCLUSIVE: BioRestorative Therapies Tells Benzinga 'License will enable expanded clinical operations for investigator-initiated trials and potential "right to try" uses of BRTX-100'
Portfolio Pulse from Benzinga Newsdesk
BioRestorative Therapies has announced that its license will enable expanded clinical operations for investigator-initiated trials and potential 'right to try' uses of BRTX-100.
May 31, 2023 | 10:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioRestorative Therapies' license expansion could lead to increased clinical operations and potential new uses for BRTX-100.
The license expansion for BioRestorative Therapies allows for increased clinical operations and potential new uses for BRTX-100. This could lead to more trials, increased adoption, and ultimately a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100